Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Large ribosomal subunit protein uL30m (MRPL30) is a protein encoded by the nuclear genome and imported into mitochondria, where it forms part of the 39S large subunit of the mitochondrial ribosome (mitoribosome)[1][3][6]. It is essential for mitochondrial protein synthesis, facilitating the translation of mitochondrial genome-encoded proteins, which are crucial for cellular energy production via oxidative phosphorylation[1][3][5]. MRPL30 does not have a recognized direct role as a therapeutic target, nor are there known drugs directly interacting with it. However, perturbations in mitochondrial ribosomal proteins as a group, including MRPL30, may be implicated in mitochondrial diseases and, in some contexts, cancer biology[5]. The mitochondrial ribosomal proteins are distinct from their cytoplasmic counterparts in structure and sequence, and their deficiency may disrupt mitochondrial function[1][3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Large ribosomal subunit protein uL30m (MRPL30).